The tweet was deleted by the author.
But we saved everything 🙂.
MBX Biosciences, Inc. has reaffirmed its commitment to science-driven innovation in recognition of World Health Day. The company is leveraging its proprietary PEP Platform to reshape the treatment landscape for endocrine and metabolic diseases.
By supporting the World Health Organization's call to stand with science, MBX Biosciences, Inc. signals a research-focused approach to developing new therapies. The company intends to drive progress in addressing unmet needs for patients affected by these chronic health conditions.
Earlier this year, MBX Biosciences completed an End-of-Phase 2 meeting with the FDA for its once-weekly chronic hypoparathyroidism therapy trial, according to a company statement. Executives also met with investors at Jefferies and Barclays healthcare conferences, offering webcast access for updates on development progress earlier this season. These activities reflect the company’s ongoing engagement with regulators and the investment community.